Ge Ivy Y, Fevrier Helene B, Conell Carol, Kheraj Malika N, Flint Alexander C, Smith Darvin S, Herrinton Lisa J
Inpatient Pharmacy, Kaiser Permanente Northern California South San Francisco Medical Center, 1200 El Camino Real, 3rd Floor, South San Francisco, CA 94080, USA.
Division of Research, Kaiser Permanente, Oakland, CA, USA.
Ther Adv Urol. 2018 Jun 22;10(10):283-293. doi: 10.1177/1756287218783871. eCollection 2018 Oct.
Risk of community-acquired infection (CA-CDI) following antibiotic treatment specifically for urinary tract infection (UTI) has not been evaluated.
We conducted a nested case-control study at Kaiser Permanente Northern California, 2007-2010, to assess antibiotic prescribing and other factors in relation to risk of CA-CDI in outpatients with uncomplicated UTI. Cases were diagnosed with CA-CDI within 90 days of antibiotic use. We used matched controls and confirmed case-control eligibility through chart review. Antibiotics were classified as ciprofloxacin (most common), or low risk (nitrofurantoin, sulfamethoxazole/trimethoprim), moderate risk, or high risk (e.g. cefpodoxime, ceftriaxone, clindamycin) for CDI. We computed the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the relationship of antibiotic treatment for uncomplicated UTI and history of relevant gastrointestinal comorbidity (including gastrointestinal diagnoses, procedures, and gastric acid suppression treatment) with risk of CA-CDI using logistic regression analysis.
Despite the large population, only 68 cases were confirmed with CA-CDI for comparison with 112 controls. Female sex [81% of controls, adjusted odds ratio (OR) 6.3, CI 1.7-24), past gastrointestinal comorbidity (prevalence 39%, OR 2.3, CI 1.1-4.8), and nongastrointestinal comorbidity (prevalence 6%, OR 2.8, CI 1.4-5.6) were associated with increased CA-CDI risk. Compared with low-risk antibiotic, the adjusted ORs for antibiotic groups were as follows: ciprofloxacin, 2.7 (CI 1.0-7.2); moderate-risk antibiotics, 3.6 (CI 1.2-11); and high-risk antibiotics, 11.2 (CI 2.4-52).
Lower-risk antibiotics should be used for UTI whenever possible, particularly in patients with a gastrointestinal comorbidity. However, UTI can be managed through alternative approaches. Research into the primary prevention of UTI is urgently needed.
专门针对尿路感染(UTI)进行抗生素治疗后发生社区获得性感染(CA-CDI)的风险尚未得到评估。
2007年至2010年,我们在北加利福尼亚州凯撒医疗机构进行了一项巢式病例对照研究,以评估抗生素处方及其他因素与单纯性UTI门诊患者发生CA-CDI风险之间的关系。病例为在使用抗生素后90天内被诊断为CA-CDI的患者。我们采用匹配对照,并通过病历审查确认病例对照的合格性。抗生素被分类为环丙沙星(最常用)、低风险(呋喃妥因、磺胺甲恶唑/甲氧苄啶)、中度风险或高风险(如头孢泊肟、头孢曲松、克林霉素)引发CDI的药物。我们使用逻辑回归分析计算单纯性UTI抗生素治疗及相关胃肠道合并症病史(包括胃肠道诊断、手术及胃酸抑制治疗)与CA-CDI风险关系的校正比值比(OR)和95%置信区间(CI)。
尽管研究人群庞大,但仅确诊68例CA-CDI病例用于与112例对照进行比较。女性(占对照的81%,校正比值比(OR)为6.3,CI为1.7 - 24)、既往胃肠道合并症(患病率39%,OR为2.3,CI为1.1 - 4.8)以及非胃肠道合并症(患病率6%,OR为2.8,CI为1.4 - 5.6)与CA-CDI风险增加相关。与低风险抗生素相比,各抗生素组的校正OR如下:环丙沙星,2.7(CI为1.0 - 7.2);中度风险抗生素,3.6(CI为1.2 - 11);高风险抗生素,11.2(CI为2.4 - 52)。
只要有可能,应使用低风险抗生素治疗UTI,尤其是有胃肠道合并症的患者。然而,UTI可通过其他方法进行管理。迫切需要对UTI的一级预防进行研究。